167 related articles for article (PubMed ID: 22824940)
1. Biodegradable PLGA85/15 nanoparticles as a delivery vehicle for Chlamydia trachomatis recombinant MOMP-187 peptide.
Taha MA; Singh SR; Dennis VA
Nanotechnology; 2012 Aug; 23(32):325101. PubMed ID: 22824940
[TBL] [Abstract][Full Text] [Related]
2. Chlamydia trachomatis recombinant MOMP encapsulated in PLGA nanoparticles triggers primarily T helper 1 cellular and antibody immune responses in mice: a desirable candidate nanovaccine.
Fairley SJ; Singh SR; Yilma AN; Waffo AB; Subbarayan P; Dixit S; Taha MA; Cambridge CD; Dennis VA
Int J Nanomedicine; 2013; 8():2085-99. PubMed ID: 23785233
[TBL] [Abstract][Full Text] [Related]
3. Poly(lactic acid)-poly(ethylene glycol) nanoparticles provide sustained delivery of a Chlamydia trachomatis recombinant MOMP peptide and potentiate systemic adaptive immune responses in mice.
Dixit S; Singh SR; Yilma AN; Agee RD; Taha M; Dennis VA
Nanomedicine; 2014 Aug; 10(6):1311-21. PubMed ID: 24602605
[TBL] [Abstract][Full Text] [Related]
4. A nanovaccine formulation of Chlamydia recombinant MOMP encapsulated in PLGA 85:15 nanoparticles augments CD4
Sahu R; Dixit S; Verma R; Duncan SA; Coats MT; Giambartolomei GH; Singh SR; Dennis VA
Nanomedicine; 2020 Oct; 29():102257. PubMed ID: 32610072
[TBL] [Abstract][Full Text] [Related]
5. Formulation, characterization, and expression of a recombinant MOMP Chlamydia trachomatis DNA vaccine encapsulated in chitosan nanoparticles.
Cambridge CD; Singh SR; Waffo AB; Fairley SJ; Dennis VA
Int J Nanomedicine; 2013; 8():1759-71. PubMed ID: 23690681
[TBL] [Abstract][Full Text] [Related]
6. Encapsulation of Recombinant MOMP in Extended-Releasing PLGA 85:15 Nanoparticles Confer Protective Immunity Against a
Sahu R; Dixit S; Verma R; Duncan SA; Smith L; Giambartolomei GH; Singh SR; Dennis VA
Front Immunol; 2021; 12():660932. PubMed ID: 33936096
[TBL] [Abstract][Full Text] [Related]
7. Effect of thiol functionalization on the hemo-compatibility of PLGA nanoparticles.
Thasneem YM; Sajeesh S; Sharma CP
J Biomed Mater Res A; 2011 Dec; 99(4):607-17. PubMed ID: 21953904
[TBL] [Abstract][Full Text] [Related]
8. Chitosan-modified poly(D,L-lactide-co-glycolide) nanospheres for plasmid DNA delivery and HBV gene-silencing.
Zeng P; Xu Y; Zeng C; Ren H; Peng M
Int J Pharm; 2011 Aug; 415(1-2):259-66. PubMed ID: 21645597
[TBL] [Abstract][Full Text] [Related]
9. Modified nanoprecipitation method to fabricate DNA-loaded PLGA nanoparticles.
Niu X; Zou W; Liu C; Zhang N; Fu C
Drug Dev Ind Pharm; 2009 Nov; 35(11):1375-83. PubMed ID: 19832638
[TBL] [Abstract][Full Text] [Related]
10. Recombinant expression of Chlamydia trachomatis major outer membrane protein in E. Coli outer membrane as a substrate for vaccine research.
Wen Z; Boddicker MA; Kaufhold RM; Khandelwal P; Durr E; Qiu P; Lucas BJ; Nahas DD; Cook JC; Touch S; Skinner JM; Espeseth AS; Przysiecki CT; Zhang L
BMC Microbiol; 2016 Jul; 16(1):165. PubMed ID: 27464881
[TBL] [Abstract][Full Text] [Related]
11. Microencapsulation of inorganic nanocrystals into PLGA microsphere vaccines enables their intracellular localization in dendritic cells by electron and fluorescence microscopy.
Schliehe C; Schliehe C; Thiry M; Tromsdorf UI; Hentschel J; Weller H; Groettrup M
J Control Release; 2011 May; 151(3):278-85. PubMed ID: 21223984
[TBL] [Abstract][Full Text] [Related]
12. PLGA-Chitosan Encapsulated IL-10 Nanoparticles Modulate Chlamydia Inflammation in Mice.
Yilma AN; Sahu R; Subbarayan P; Villinger F; Coats MT; Singh SR; Dennis VA
Int J Nanomedicine; 2024; 19():1287-1301. PubMed ID: 38348174
[TBL] [Abstract][Full Text] [Related]
13. Nanoparticles of lipid monolayer shell and biodegradable polymer core for controlled release of paclitaxel: effects of surfactants on particles size, characteristics and in vitro performance.
Liu Y; Pan J; Feng SS
Int J Pharm; 2010 Aug; 395(1-2):243-50. PubMed ID: 20472049
[TBL] [Abstract][Full Text] [Related]
14. Preparation of peptide microspheres using tumor antigen-derived peptides.
Bhatnagar S; Naqvi RA; Ali R; Rao DN
Methods Mol Biol; 2014; 1139():443-52. PubMed ID: 24619698
[TBL] [Abstract][Full Text] [Related]
15. Surface modification of poly(D,L-lactic-co-glycolic acid) nanoparticles with protamine enhanced cross-presentation of encapsulated ovalbumin by bone marrow-derived dendritic cells.
Han R; Zhu J; Yang X; Xu H
J Biomed Mater Res A; 2011 Jan; 96(1):142-9. PubMed ID: 21105162
[TBL] [Abstract][Full Text] [Related]
16. A novel hybrid delivery system: polymer-oil nanostructured carrier for controlled delivery of highly lipophilic drug all-trans-retinoic acid (ATRA).
Narvekar M; Xue HY; Wong HL
Int J Pharm; 2012 Oct; 436(1-2):721-31. PubMed ID: 22850294
[TBL] [Abstract][Full Text] [Related]
17. Fabrication of curcumin encapsulated PLGA nanoparticles for improved therapeutic effects in metastatic cancer cells.
Yallapu MM; Gupta BK; Jaggi M; Chauhan SC
J Colloid Interface Sci; 2010 Nov; 351(1):19-29. PubMed ID: 20627257
[TBL] [Abstract][Full Text] [Related]
18. Biodegradable polymeric system for cisplatin delivery: development, in vitro characterization and investigation of toxicity profile.
Alam N; Khare V; Dubey R; Saneja A; Kushwaha M; Singh G; Sharma N; Chandan B; Gupta PN
Mater Sci Eng C Mater Biol Appl; 2014 May; 38():85-93. PubMed ID: 24656356
[TBL] [Abstract][Full Text] [Related]
19. trans-[Ru(NO)Cl(cyclam)](PF6)2 and [Ru(NO)(Hedta)] incorporated in PLGA nanoparticles for the delivery of nitric oxide to B16-F10 cells: cytotoxicity and phototoxicity.
Gomes AJ; Espreafico EM; Tfouni E
Mol Pharm; 2013 Oct; 10(10):3544-54. PubMed ID: 23865934
[TBL] [Abstract][Full Text] [Related]
20. Comparison of humoral and cell-mediated immune responses to cationic PLGA microspheres containing recombinant hepatitis B antigen.
Saini V; Jain V; Sudheesh MS; Jaganathan KS; Murthy PK; Kohli DV
Int J Pharm; 2011 Apr; 408(1-2):50-7. PubMed ID: 21291968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
